VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Human cytomegalovirus DNA vaccine VCL-CB01 encoding phosphoprotein 65 and gB
Vaccine Information
  • Vaccine Ontology ID: VO_0004341
  • Type: DNA vaccine
  • Status: Clinical trial
  • Host Species as Laboratory Animal Model: Human
  • Glycoprotein B gene engineering:
    • Type: DNA vaccine construction
    • Description: This DNA vaccine expressed the major hCMV surface glycoprotein B (Schleiss, 2009).
    • Detailed Gene Information: Click Here.
  • UL83 gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Human Response

  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: VCL-CB01 increased T-cell responses compared with placebo (Schleiss, 2009).

Mouse Response

  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: Preclinical investigation of the hCMV gB/pp65 DNA vaccine was initially conducted in mice. When formulated in PBS, lone gB and pp65 plasmids were highly immunogenic, but vaccination with the bivalent vaccine reduced immune responses to each antigen by 2.8- and 4-fold of the lone values, respectively. However, formulating the bivalent vaccine with 02A significantly (p = 0.048) increased the antigen-specific immune responses relative to those induced with the bivalent vaccine in PBS, as well as completely abrogating a decrease in pp65-specific T-cell responses (Schleiss, 2009).
References